RhumbLine Advisers
GALT icon

RhumbLine Advisers’s Galectin Therapeutics GALT Stock Holding History

RhumbLine Advisers’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$224K Buy
+48,332
New +$125K ﹤0.01% 3223
2025
Q2 		– Sell
-16,401
Closed -$20K – 4184
2025
Q1 		$20K Sell
16,401
-1,129
-6% -$1.58K ﹤0.01% 3738
2024
Q4 		$22.6K Buy
17,530
+120
+0.7% +$288 ﹤0.01% 3788
2024
Q3 		$47.9K Sell
17,410
-1,865
-10% -$4.58K ﹤0.01% 3686
2024
Q2 		$43.6K Buy
+19,275
New +$58.6K ﹤0.01% 3718
2021
Q2 		– Sell
-30,689
Closed -$67K – 3036
2021
Q1 		$67K Buy
30,689
+2,425
+9% +$5.43K ﹤0.01% 2966
2020
Q4 		$63K Buy
28,264
+2,830
+11% +$7.43K ﹤0.01% 3011
2020
Q3 		$68K Sell
25,434
-6,365
-20% -$17.8K ﹤0.01% 2931
2020
Q2 		$97K Buy
31,799
+1,001
+3% +$2.52K ﹤0.01% 2974
2020
Q1 		$60K Hold
30,798
– – ﹤0.01% 2843
2019
Q4 		$88K Buy
30,798
+3,468
+13% +$12.1K ﹤0.01% 2883
2019
Q3 		$100K Buy
27,330
+75
+0.3% +$271 ﹤0.01% 2885
2019
Q2 		$113K Buy
+27,255
New +$118K ﹤0.01% 2911
2015
Q2 		– Sell
-17,755
Closed -$59K – 3046
2015
Q1 		$59K Buy
17,755
+3,400
+24% +$12.1K ﹤0.01% 2990
2014
Q4 		$50K Buy
14,355
+425
+3% +$1.88K ﹤0.01% 2992
2014
Q3 		$70K Hold
13,930
– – ﹤0.01% 2951
2014
Q2 		$192K Buy
+13,930
New +$173K ﹤0.01% 2853

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

RhumbLine Advisers's GALT Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 48,332 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #3223 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in GALT as recently as Q1 2025.

RhumbLine Advisers first reported a position in GALT in Q2 2014 and has held it in 17 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • RhumbLine Advisers held 48,332 shares of Galectin Therapeutics worth $224K as of Q2 2026.
  • Galectin Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3223 holding.
  • RhumbLine Advisers first reported a position in Galectin Therapeutics in Q2 2014 and has held it in 17 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.